RESEARCH ARTICLE


Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis



Yoshiyuki Morishita 1, *, Eiji Kusano 2, Daisuke Nagata 1
1 Division of Nephrology, Department of Medicine, Jichi Medical University, Tochigi, Japan
2 Utsunomiya Social Insurance Hospital, Tochigi, Japan


Article Metrics

CrossRef Citations:
1
Total Statistics:

Full-Text HTML Views: 1660
Abstract HTML Views: 770
PDF Downloads: 375
Total Views/Downloads: 2805
Unique Statistics:

Full-Text HTML Views: 810
Abstract HTML Views: 429
PDF Downloads: 260
Total Views/Downloads: 1499



Creative Commons License
© Morishita et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Division of Nephrology, Department of Medicine, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke-city, Tochigi 329-0498, Japan; Tel.: 81-285-44-4869, Fax: 81-285-44-4869; E-mail: ymori@jichi.ac.jp


Abstract

The renin-angiotensin-aldosterone system (RAAS) blockers have been widely used in chronic kidney disease patients undergoing hemodialysis; however, whether RAAS blockers have beneficial effects for cardiovascular disease in those patients has not been fully defined. This review focuses on the effects of RAAS blockers in chronic kidney disease undergoing hemodialysis for cardiovascular disease.

Keywords: Hemodialysis, clinical study, renin, angiotensin I, angiotensin II, aldosterone, angiotensin-converting enzyme inhibitor, angiotensin receptor blockers, direct renin inhibitor, cardiovascular disease..